Achieving Allocative Efficiency in Healthcare: Nice in Theory, not so NICE in Practice?

Mike Paulden; Christopher McCabe; Jonathan Karnon

doi:10.1007/s40273-014-0146-x

Achieving Allocative Efficiency in Healthcare: Nice in Theory, not so NICE in Practice?

Mike Paulden, Christopher McCabe, Jonathan Karnon

Research output: Contribution to journal › Review article

6 Citations (Scopus)

Abstract

Eckermann and Pekarsky have written a thought-provoking paper that challenges a number of existing concepts, including methods for determining the cost-effectiveness threshold for appraising new health technologies for potential adoption into a public healthcare system.

Previously proposed approaches to defining the threshold have included the estimation of the societal monetary value of a QALY to inform the net monetary benefits of new technologies, where the technology is funded if the net benefits are positive. Alternative approaches aim to represent opportunity cost, either by focusing on the QALYs forgone from the displacement of services to generate resources to fund new technologies, or as a retrospective estimate of expected QALY gains from budget expansion or contraction at the margin

Original language	English
Pages (from-to)	315-318
Number of pages	4
Journal	Pharmacoeconomics
Volume	32
Issue number	4
DOIs	https://doi.org/10.1007/s40273-014-0146-x
Publication status	Published - Apr 2014
Externally published	Yes

Keywords

Cost-effectiveness
QALY
monetary benefits

Access to Document

10.1007/s40273-014-0146-xLicence: In Copyright

Link to publication in Scopus

Fingerprint Dive into the research topics of 'Achieving Allocative Efficiency in Healthcare: Nice in Theory, not so NICE in Practice?'. Together they form a unique fingerprint.

Cite this

Paulden, M., McCabe, C., & Karnon, J. (2014). Achieving Allocative Efficiency in Healthcare: Nice in Theory, not so NICE in Practice? Pharmacoeconomics, 32(4), 315-318. https://doi.org/10.1007/s40273-014-0146-x

@article{5f611a13e4514316a5275cded9a5b283,

title = "Achieving Allocative Efficiency in Healthcare: Nice in Theory, not so NICE in Practice?",

abstract = "Eckermann and Pekarsky have written a thought-provoking paper that challenges a number of existing concepts, including methods for determining the cost-effectiveness threshold for appraising new health technologies for potential adoption into a public healthcare system.Previously proposed approaches to defining the threshold have included the estimation of the societal monetary value of a QALY to inform the net monetary benefits of new technologies, where the technology is funded if the net benefits are positive. Alternative approaches aim to represent opportunity cost, either by focusing on the QALYs forgone from the displacement of services to generate resources to fund new technologies, or as a retrospective estimate of expected QALY gains from budget expansion or contraction at the margin ",

keywords = "Cost-effectiveness, QALY, monetary benefits",

author = "Mike Paulden and Christopher McCabe and Jonathan Karnon",

year = "2014",

month = apr,

doi = "10.1007/s40273-014-0146-x",

language = "English",

volume = "32",

pages = "315--318",

journal = "Pharmacoeconomics",

issn = "1170-7690",

publisher = "Springer International Publishing",

number = "4",

}

TY - JOUR

T1 - Achieving Allocative Efficiency in Healthcare

T2 - Nice in Theory, not so NICE in Practice?

AU - Paulden, Mike

AU - McCabe, Christopher

AU - Karnon, Jonathan

PY - 2014/4

Y1 - 2014/4

N2 - Eckermann and Pekarsky have written a thought-provoking paper that challenges a number of existing concepts, including methods for determining the cost-effectiveness threshold for appraising new health technologies for potential adoption into a public healthcare system.Previously proposed approaches to defining the threshold have included the estimation of the societal monetary value of a QALY to inform the net monetary benefits of new technologies, where the technology is funded if the net benefits are positive. Alternative approaches aim to represent opportunity cost, either by focusing on the QALYs forgone from the displacement of services to generate resources to fund new technologies, or as a retrospective estimate of expected QALY gains from budget expansion or contraction at the margin

AB - Eckermann and Pekarsky have written a thought-provoking paper that challenges a number of existing concepts, including methods for determining the cost-effectiveness threshold for appraising new health technologies for potential adoption into a public healthcare system.Previously proposed approaches to defining the threshold have included the estimation of the societal monetary value of a QALY to inform the net monetary benefits of new technologies, where the technology is funded if the net benefits are positive. Alternative approaches aim to represent opportunity cost, either by focusing on the QALYs forgone from the displacement of services to generate resources to fund new technologies, or as a retrospective estimate of expected QALY gains from budget expansion or contraction at the margin

KW - Cost-effectiveness

KW - QALY

KW - monetary benefits

UR - http://www.scopus.com/inward/record.url?scp=84897501016&partnerID=8YFLogxK

U2 - 10.1007/s40273-014-0146-x

DO - 10.1007/s40273-014-0146-x

M3 - Review article

VL - 32

SP - 315

EP - 318

JO - Pharmacoeconomics

JF - Pharmacoeconomics

SN - 1170-7690

IS - 4

ER -